ArticleTranslational lung cancer research2019

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.

Lili Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.